News stories about Bioverativ (NASDAQ:BIVV) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioverativ earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5805836706772 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- American Airlines Group Inc. (AAL) Regains Attentions on Diverse News- Bioverativ Inc. (BIVV) – Investing News Update (investingbizz.com)
- Bioverativ Sees Unusually High Options Volume (BIVV) (americanbankingnews.com)
- Active Healthcare stock – Bioverativ Inc. (BIVV) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- $0.48 EPS Expected for Bioverativ Inc. (BIVV); 3 Analysts Bullish Sonoco Products Company (SON) – Hill Country Times (hillcountrytimes.com)
- Bioverativ Announces 2018 Annual Meeting of Stockholders (finance.yahoo.com)
Several analysts have recently commented on the stock. Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Morgan Stanley reiterated an “underweight” rating and issued a $47.00 target price (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Wednesday, September 20th. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 target price on the stock in a report on Thursday, October 19th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $60.93.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis. analysts predict that Bioverativ will post 2.45 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Bioverativ (BIVV) Given Daily Media Sentiment Score of 0.14” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/26/bioverativ-bivv-given-daily-media-sentiment-score-of-0-14.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
What are top analysts saying about Bioverativ? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ and related companies.